Budesonide/procaterol

Drug Profile

Budesonide/procaterol

Alternative Names: Procaterol/budesonide; SYN-006; Synbitide HFA MDI

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intech Biopharm
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Hydroxyquinolines; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 24 Mar 2017 Budesonide/procaterol is still at phase II development stage for Asthma in Taiwan (Inhalation)
  • 08 Sep 2016 Intech Biopharm has patent protection for Budesonide/procaterol in USA, Canada, Australia, New Zealand, South Korea and Hong Kong (Intech Biopharm website, September 2016)
  • 08 Sep 2016 Intech Biopharm plans phase III trials for Asthma in countries worldwide (Intech Biopharm pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top